<DOC>
	<DOCNO>NCT02956993</DOCNO>
	<brief_summary>The research study design assess technical feasibility safety perivascular injection vonapanitase deliver via micro-infusion catheter distal popliteal , tibial peroneal artery immediately follow successful angioplasty .</brief_summary>
	<brief_title>Safety/Feasibility Vonapanitase Following Angioplasty Patients With Peripheral Artery Disease ( PAD ) Below Knee ( BTK )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Screening : Initial study inclusion criterion 1 . Age least 18 year . 2 . Clinical diagnosis PAD secondary atherosclerosis affect low limb . 3 . Rutherford category 35 . 4 . De novo lesion , previously treat angioplasty , atherectomy stenting . 5 . Scheduled undergo angioplasty distal popliteal , tibial peroneal artery . 6 . If female childbearing potential ( premenopausal surgically sterile ) must negative pregnancy test screen visit willing use contraception time screen visit 1 week follow study drug administration . Acceptable method birth control include abstinence , barrier method spermicide , implant , injectables , oral contraceptive , intrauterine device , vasectomized partner . 7 . Ability understand comply requirement entire study communicate study team . 8 . Ability provide write informed consent use document approve required institutional review board . Procedure : Study inclusion criterion determine time angioplasty procedure 9 . Atherosclerotic lesion &gt; 50 % stenosis popliteal ( distal center knee joint space , P3 segment ) , tibial peroneal artery prior angioplasty . 10 . Successful revascularization without use stenting target lesion ; flow limit dissection &lt; 30 % residual lumen stenosis compare adjacent nondiseased lumen diameter . Exclusion Criteria Screening : Initial study exclusion criterion 1 . Patients arterial insufficiency lower extremity result immunologic inflammatory nonatherosclerotic disorder ( e.g. , Buerger 's disease , vasculitis ) . 2 . Planned ankle amputation ipsilateral limb within 4 week study drug administration . 3 . Prior plan stenting target lesion . 4 . Deep vein thrombosis within past 3 month . 5 . Known bleed disorder . 6 . Known hypercoagulable state ( e.g. , protein C deficiency , factor V Leiden , prothrombin G20210A mutation ) . 7 . Platelet count &lt; 130K , hematocrit &lt; 30 % , bilirubin ALT &gt; 3.0 time upper limit normal . 8 . Renal failure exist dependence dialysis eGFR MDRD calculation &lt; 20 mL/min/1.73 m2 . 9 . Pregnancy , lactation plan become pregnant course study . 10 . Presence significant medical condition might significantly confound collection safety efficacy data study . 11 . Malignancy treatment malignancy within previous 12 month exception localize basal cell squamous cell skin cancer , cancer situ . 12 . Treatment investigational drug within previous 30 day investigational antibody therapy within 90 day prior sign inform consent . 13 . Known allergy radiocontrast agent . Procedure : Exclusion criterion determine time angioplasty procedure 14 . Reference vessel diameter &lt; 2 mm &gt; 8 mm . 15 . Severe concentric medial calcification target lesion think interfere study drug delivery adventitia base fluoroscopic appearance . 16 . Aneurysm target vessel . 17 . Failure cross target lesion guide wire ; however subintimal wire crossing allow . 18 . Stenting target lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>peripheral artery disease</keyword>
	<keyword>PAD</keyword>
	<keyword>vonapanitase</keyword>
	<keyword>critical limb ischemia</keyword>
	<keyword>CLI</keyword>
	<keyword>tibial artery</keyword>
	<keyword>stenosis</keyword>
	<keyword>distal popliteal artery</keyword>
	<keyword>peroneal artery</keyword>
	<keyword>knee</keyword>
	<keyword>BTK</keyword>
	<keyword>elastase</keyword>
	<keyword>chymotrypsin-like elastase 1</keyword>
	<keyword>CELA1</keyword>
	<keyword>PRT-201</keyword>
</DOC>